Baxter International Inc. (BAX)

Check out top investors' recommendation for BAX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
90.00
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company operates in two segments, BioScience and Medical Products. The BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. It also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies; and to treat end-stage renal disease or irreversible kidney failure. In addition, this segment manufactures solutions and other products for peritoneal dialysis, a home-based therapy; and distributes products for hemodialysis, which is conducted in a hospital or clinic. Baxter International Inc. serves hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients at home under physician supervision in the United States, Europe, the Asia-Pacific, Latin America, and Canada. The company sells its products through its direct sales force, as well as to and through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. Baxter International Inc. was founded in 1931 and is based in Deerfield, Illinois.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Larry Biegelsen Wells Fargo Securities, Llc Buy   Jun 25, '19       Jun 25, '20  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Jun 20, '19     90.00  Jun 20, '20  N/A 
David Lewis Morgan Stanley Buy   Mar 05, '19     83.00  Mar 05, '20  N/A 
Matt Miksic Piper Jaffray Buy   Feb 04, '19     79.00  Feb 04, '20  N/A 
Joanne Wuensch BMO Capital Markets Buy   Feb 01, '19     80.00  Feb 01, '20  N/A 
Lawrence Keusch Raymond James Buy   Feb 01, '19     80.00  Feb 01, '20  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Feb 01, '19     80.00  Feb 01, '20  N/A 
Matthew Taylor National Bank Financial Buy   Feb 01, '19     84.00  Feb 01, '20  N/A 
David Lewis Morgan Stanley Buy   Jan 02, '19     77.00  Jan 02, '20  N/A 
Amit Hazan Suntrust Robinson Humphrey Buy   Jan 02, '19     76.00  Jan 02, '20  N/A 
David Lewis Morgan Stanley Sell   Oct 11, '18     75.00  Oct 11, '19  N/A 
Bob Hopkins BofA Merrill Lynch Buy   May 22, '18     83.00  May 22, '19  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   May 22, '18     77.00  May 22, '19  N/A 
Kristen Stewart Deutsche Bank Securities Buy   Feb 20, '18     80.00  Feb 20, '19  N/A 
Matthew Taylor National Bank Financial Buy   Feb 02, '18     77.00  Feb 02, '19  N/A 
Lawrence Keusch Raymond James Buy   Jan 03, '18       Jan 03, '19  N/A 
Bob Hopkins BofA Merrill Lynch Buy   Jan 02, '18     73.00  Jan 02, '19  N/A 
Joanne Wuensch BMO Capital Markets Buy   Nov 13, '17     70.00  Nov 13, '18  N/A 
Matthew Taylor National Bank Financial Buy   Oct 26, '17     73.00  Oct 26, '18  N/A 
David Lewis Morgan Stanley Sell   Oct 13, '17       Oct 13, '18  N/A 
< previous123